Velaglucerase alfa

被引：22

作者：

Aerts, Johannes M. F. G. ^{[1
]}

Yasothan, Uma ^{[2
]}

Kirkpatrick, Peter

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 11期

关键词：

REPLACEMENT THERAPY; GAUCHER-DISEASE;

D O I：

10.1038/nrd3311

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In February 2010, velaglucerase alfa (Vpriv; Shire) was approved by the US Food and Drug Administration as a long-term enzyme replacement therapy for paediatric and adult patients with type 1 Gaucher's disease. It was granted marketing authorization by the European Commission for the same indication in August 2010.

引用

页码：837 / 838

页数：2

共 21 条

[1] A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme-A Preclinical and Phase I Investigation [J].

Aviezer, David ;

Brill-Almon, Einat ;

Shaaltiel, Yoseph ;

Hashmueli, Sharon ;

Bartfeld, Daniel ;

Mizrachi, Sarah ;

Liberman, Yael ;

Freeman, Arnold ;

Zimran, Ari ;

Galun, Eithan .

PLOS ONE, 2009, 4 (03)

[2] REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE [J].

BARTON, NW ;

BRADY, RO ;

DAMBROSIA, JM ;

DIBISCEGLIE, AM ;

DOPPELT, SH ;

HILL, SC ;

MANKIN, HJ ;

MURRAY, GJ ;

PARKER, RI ;

ARGOFF, CE ;

GREWAL, RP ;

YU, KT .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1464-1470

[3] Enzyme replacement for lysosomal diseases [J].

Brady, RO .

ANNUAL REVIEW OF MEDICINE, 2006, 57 :283-296

[4] Characterization of gene-activated human acid-β-glucosidase: Crystal structure, glycan composition, and internalization into macrophages [J].

Brumshtein, Boris ;

Salinas, Paul ;

Peterson, Brian ;

Chan, Victor ;

Silman, Israel ;

Sussman, Joel L. ;

Savickas, Philip J. ;

Robinson, Gregory S. ;

Futerman, Anthony H. .

GLYCOBIOLOGY, 2010, 20 (01) :24-32

[5]

CLARK M, 2010, DTSCH BANK GLOBAL MA

[6] Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring [J].

Cox, T. M. ;

Aerts, J. M. F. G. ;

Belmatoug, N. ;

Cappellini, M. D. ;

vom Dahl, S. ;

Goldblatt, J. ;

Grabowski, G. A. ;

Hollak, C. E. M. ;

Hwu, P. ;

Maas, M. ;

Martins, A. M. ;

Mistry, P. K. ;

Pastores, G. M. ;

Tylki-Szymanska, A. ;

Yee, J. ;

Weinreb, N. .

JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 (03) :319-336

[7] Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease [J].

Elstein, D. ;

Cohn, G. M. ;

Wang, N. ;

Djordjevic, M. ;

Brutaru, C. ;

Zimran, A. .

BLOOD CELLS MOLECULES AND DISEASES, 2011, 46 (01) :119-123

[8]

*EMA, 2010, EUR PUBL ASS REP VPR

[9] Enzyme replacement therapy "drug holiday": Results from an unexpected shortage of an orphan drug supply in Australia [J].

Goldblatt, Jack ;

Fletcher, Janice M. ;

McGill, Jim ;

Szer, Jeffrey ;

Wilson, Meredith .

BLOOD CELLS MOLECULES AND DISEASES, 2011, 46 (01) :107-110

[10] Short-term withdrawal from imiglucerase: What can we learn from it? [J].

Hollak, Carla E. M. .

BLOOD CELLS MOLECULES AND DISEASES, 2011, 46 (01) :105-106

← 1 2 3 →